Compare prices and buy GLOW Blend from 43 research peptide vendors - also called suppliers or sources. Updated daily.
GHK-Cu + TB-500 + BPC-157
A three-peptide research blend combining GHK-Cu, the copper complex of the tripeptide glycyl-histidyl-lysine, with BPC-157, a 15-amino-acid fragment of a gastric protein, and TB-500, sold as either full-length thymosin beta-4 or its seven-residue 17-23 fragment depending on the vendor. The three act through unrelated mechanisms studied in cell-culture and preclinical models, and the combination has not been evaluated in a controlled human trial. Vendors typically load several times more GHK-Cu than either other component, so most of the vial's mass is the copper peptide. For research purposes only.
For research purposes only. Not medical advice.
GLOW is a fixed combination of three research peptides in one vial: GHK-Cu, BPC-157 and TB-500. It is a mixture rather than a distinct chemical entity, so it carries no CAS number of its own, and no pharmacopeia recognizes "GLOW" as a substance. The name is vendor branding.
The formula is lopsided. A 70 mg vial holds 50 mg of GHK-Cu and 10 mg each of BPC-157 and TB-500, and where a vendor appends the load to the name, GLOW-70 names that total. Vials at other totals exist, so the split printed on the listing, not the trade name, states each component's load. GLOW sits between Wolverine, which is the BPC-157 and TB-500 pair on its own, and KLOW, which adds KPV on top of GLOW. KLOW vs GLOW compares the two blends' compositions, each component's FDA record and their prices per vial.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-histidyl-lysine. It delivers Cu2+ to tissue, where copper acts as a cofactor for connective-tissue enzymes. In cell-culture work it modulates matrix metalloproteinase activity and upregulates collagen and decorin synthesis.
BPC-157 is a synthetic 15-amino-acid sequence corresponding to a fragment of a protein isolated from human gastric juice. The mechanisms proposed for it (modulation of nitric oxide signaling, upregulation of VEGFR2, activation of the FAK-paxillin pathway) come from cell-culture and rodent studies.
Thymosin beta-4 is a 43-residue actin-sequestering protein. By binding monomeric G-actin it shifts cytoskeletal assembly, which in laboratory wound models has been associated with cell migration and angiogenesis.
The three share no sequence, no origin and no mechanism. Selling them as a fixed trio is a market convention rather than a pharmacological one, and the combination has never been evaluated in a controlled human trial.
"TB-500" covers two molecules: full-length thymosin beta-4, CAS 77591-33-4, and the N-acetylated seven-residue TB-500 Frag 17-23, CAS 885340-08-9. A blend listing that names its component only as "TB-500" does not say which one, and the certificate of analysis is the only reliable check. The Wolverine blend page covers that ambiguity in full.
PeptideScouter records a blend's size as the total peptide content of the vial, not the load of any one component. In GLOW that total is dominated by GHK-Cu, which is roughly 70 percent of the mass in a 50/10/10 vial and is by a wide margin the least expensive of the three per milligram.
A GLOW vial's price per milligram therefore tracks the copper peptide, and setting it against a BPC-157 or TB-500 vial is not a like-for-like comparison. A blend that looks inexpensive next to a single-peptide vial is usually a bigger vial holding more of the cheaper ingredient.
None of the three components is an FDA-approved drug, and the blend as sold is not a compounded prescription product. Their compounding status diverged in 2026.
The component that makes up most of the vial is therefore the one not yet before the committee, and the GHK-Cu page tracks its review. Full-length thymosin beta-4 was not the substance at any of these steps, so none of them covered the TB-500 in a vial that holds the full chain. Our writeup of the July 2026 PCAC vote covers all seven substances heard that week.
Research-grade material sold by the vendors indexed here is offered for laboratory research use only and not for human consumption.
GLOW is a three-peptide combination of GHK-Cu, BPC-157 and TB-500 in a single vial. A 70 mg vial, the total that GLOW-70 names, holds 50 mg of GHK-Cu and 10 mg each of BPC-157 and TB-500. Vials at other totals exist, so the split printed on the listing states each component's load. GLOW is a vendor trade name rather than a scientific designation, and material sold by research peptide vendors is offered for laboratory use only, not for human consumption.
They are three points on the same ladder. Wolverine is BPC-157 plus TB-500. GLOW is that pair plus GHK-Cu, the copper tripeptide. KLOW is GLOW plus KPV, an alpha-MSH-derived anti-inflammatory tripeptide. The trade names are used consistently enough across vendors to work as a decoder, and where a number is appended, as in GLOW-70 or KLOW-80, it states the combined milligram load rather than a different formula.
A CAS Registry Number identifies a single chemical substance, and GLOW is a mixture of three. The components carry their own: GHK-Cu is 89030-95-5, BPC-157 is 137525-51-0, full-length thymosin beta-4 is 77591-33-4, and the seven-residue TB-500 fragment is 885340-08-9. A certificate of analysis for a blend should report each component separately, which is also the only way to confirm which of the two TB-500 molecules is in the vial.
The comparison takes care, because PeptideScouter records the blend's size as the total peptide content of the vial. Roughly 70 percent of a 50/10/10 GLOW vial is GHK-Cu, which costs far less per milligram than either BPC-157 or TB-500, so the blend's per-milligram figure mostly reflects the copper peptide rather than the two repair peptides. The like-for-like benchmark is a mass-weighted average of all three component prices. The price table on this page lists the blend's own listings, and each component's live prices are on its own page.
No. Nominations to the Section 503A bulk drug substances list are made per substance, and no combination product was before the Pharmacy Compounding Advisory Committee at its July 23-24, 2026 meeting. BPC-157 was, and so was TB-500 in its seven-residue fragment form, and the committee voted to recommend adding both. Full-length thymosin beta-4 was not on the agenda. GHK-Cu was not among the seven substances heard, so the component that makes up most of the vial has not yet been before the committee. Those votes are advisory, the FDA changes the list only through notice-and-comment rulemaking, and none of it applies to research-grade material sold by peptide vendors.
GLOW Blend is sold by 43 research peptide vendors indexed on PeptideScouter, with 65 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
41 of the 43 indexed vendors currently have GLOW Blend in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Studz Peptides currently lists GLOW Blend at $0.49/mg, the lowest listed price across 43 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $0.40/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. 42 of the 43 vendors listing GLOW Blend publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $0.49/mg listed to $0.40/mg at Pepvida Labs. Each vendor's code is shown beside its price in the table above.
GLOW Blend ranges from $0.49/mg to $3.00/mg across 65 listings from 43 research peptide vendors, normalized to USD per milligram and refreshed daily.
43 research peptide vendors currently list GLOW Blend on PeptideScouter, with 41 in stock right now. We track 65 listings across size and kit variants.
